Overview

• An SEC 8-K disclosed that oral Mira-55 normalized pain responses and significantly reduced inflammation in a formalin-induced rat model, outperforming injected morphine.
• MIRA shares jumped roughly 69–70% after hours to about $2.23 and traded up about 58% Thursday with nearly 99 million shares changing hands and an intraday high of $2.45.
• Mira reported this was the first time it directly measured inflammation alongside pain in the Mira-55 program, citing CB2 receptor mechanisms and no opioid-like sedation in the preclinical work.
• The company says the results will support an Investigational New Drug application for chronic inflammatory pain, with timing for human studies not disclosed.
• Retail interest surged on social platforms following the filing, and the small-cap firm, which reported no Q2 revenue, is slated to report Q3 results on Nov. 11.